Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder
- Conditions
- Bipolar I Disorder
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 251
- Registration Number
- NCT00238485
An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 285
- Registration Number
- NCT00237263
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 588
- Registration Number
- NCT00237237
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇩🇪Investigative Centers, Nurnberg, Germany
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
- Conditions
- Prediabetic State
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 171
- Registration Number
- NCT00237250
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)
- Conditions
- Chronic Myelogenous Leukemia in Chronic Phase
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 100
- Registration Number
- NCT00237120
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 204
- Registration Number
- NCT00234637
- Locations
- 🇫🇷
Département de Gérontologie Clinique, Limoges, Cedex, France
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
- Conditions
- Dyspepsia
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1296
- Registration Number
- NCT00232089
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Study of Omalizumab in Moderate to Severe Bronchial Asthma
- Conditions
- Asthma
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 327
- Registration Number
- NCT00232050
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
- Conditions
- Dyspepsia
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2008-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 423
- Registration Number
- NCT00232102
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
- Conditions
- Dyspepsia
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2008-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1296
- Registration Number
- NCT00232024
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States